DVx Inc. Reports Non-Consolidated Earnings Results for the Year Ended March 31, 2016; Provides Non-Consolidated Earnings Guidance for the First Half Ending September 30, 2016 and Full Year Ending March 31, 2017
May 13, 2016
Share
DVx Inc. reported non-consolidated earnings results for the year ended March 31, 2016. For the year, the company reported net sales of JPY 31,372 million compared to JPY 28,647 million a year ago. Operating income was JPY 1,492 million compared to JPY 1,429 million a year ago. Ordinary income was JPY 1,460 million compared to JPY 1,458 million a year ago. Profit was JPY 1,289 million compared to JPY 919 million a year ago. Net income per share was JPY 114.36 compared to JPY 81.57 a year ago. Net cash provided by operating activities was JPY 1,311.93 million compared to JPY 515.84 million a year ago. Profit before income taxes was JPY 1,919.15 million compared to JPY 1,451.06 million a year ago. Purchase of property, plant and equipment was JPY 144.93 million compared to JPY 107.59 million a year ago. Purchase of intangible assets was JPY 29.66 million compared to JPY 38.59 million a year ago.
The company provided non-consolidated earnings guidance for the first half ending September 30, 2016 and full year ending March 31, 2017. For the first half, the company expects net sales of JPY 15,904 million, operating income of JPY 602 million, ordinary income of JPY 602 million and profit of JPY 403 million or JPY 35.80 per share.
For the year, the company expects net sales of JPY 33,200 million, operating income of JPY 1,536 million, ordinary income of JPY 1,536 million and profit of JPY 1,028 million or JPY 91.17 per share.
DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.
DVx Inc. Reports Non-Consolidated Earnings Results for the Year Ended March 31, 2016; Provides Non-Consolidated Earnings Guidance for the First Half Ending September 30, 2016 and Full Year Ending March 31, 2017